Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia

(2016) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Mechanisms of action and resistance for multiple myeloma novel drug treatments

(2016) Shinsuke Iida   INTERNATIONAL JOURNAL OF HEMATOLOGY

Novel agents in the treatment of multiple myeloma: a review about the future

(2016) Leonard Naymagon et al.   Journal of Hematology & Oncology

Treatment options for relapsed and refractory multiple myeloma

(2015) A. K. Nooka et al.   BLOOD

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

Molecules in medicine mini-review: isoforms of PI3K in biology and disease

(2015) Bart Vanhaesebroeck et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells

(2015) Seiichi Okabe et al.   Oncotarget

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib

(2014) Ilyas Sahin et al.   AMERICAN JOURNAL OF HEMATOLOGY

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

(2014) A. Spencer et al.   BLOOD

Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition

(2014) N. Mimura et al.   CANCER RESEARCH

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Multiple myeloma

(2013) D. Smith et al.   BMJ-British Medical Journal

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Bone Marrow-Derived Mesenchymal Stromal Cells are Attracted by Multiple Myeloma Cell-Produced Chemokine CCL25 and Favor Myeloma Cell Growth in Vitro and In Vivo

(2011) Song Xu et al.   STEM CELLS